IP Library › Granted Patent US 10,251,819
Granted Patent B2
US 10,251,819 · App. 15/525,838 · Granted Apr 9, 2019

Amphiphilic polymer

Inventors: Jeong Ae Yoon (Daejeon, KR); Su Jeong Kim (Daejeon, KR); Sun Hwa Lee (Daejeon, KR); Woo Sun Shim (Daejeon, KR); Sung Soo Yoon (Daejeon, KR); Chang Hwan Ju (Daejeon, KR); Jung A Kim (Daejeon, KR); Nae Gyu Kang (Daejeon, KR)
Assignees: LG Chem, Ltd.; LG Household & Health Care Ltd.
A61K8/02A61K8/06A61K8/72A61K9/107A61K9/51C08F293/00C08F293/005C08G81/00C08F26/10C08F2438/01C08G12/06C08G65/34
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,251,819
App. No.
15/525,838
Granted
Apr 9, 2019
Kind
B2
Abstract

The present application relates to an amphiphilic polymer and a method of preparing the same. Furthermore, the present application relates to a micelle including a drug encapsulated by the amphiphilic polymer and a composition including the same. The amphiphilic polymer according to the present application has excellent drug encapsulation properties as well as good dispersion properties in an aqueous solution.

Claims (25)

1. A micelle comprising:

an amphiphilic polymer, and

a drug encapsulated by the amphiphilic polymer,

wherein the amphiphilic polymer comprises a triblock (B-A-B) which includes a first block (A); and a second block (B) which is phase-separated from the first block (A) and positioned at both sides of the first block (A),

wherein the first block (A) includes a polymer having a solubility parameter of 10.0 (cal/cm 3 ) 1/2 or more, and the second block (B) includes a polymerization unit (B1) of an acrylic monomer or vinyl-based monomer of which a homopolymer has a solubility parameter of less than 10.0 (cal/cm 3 ) 1/2 , and a polymerization unit (B2) of a polymerizable monomer having a functional group which is capable of forming a hydrogen bond,

wherein the drug includes an insoluble biologically active substance,

wherein the insoluble biologically active substance is one or more selected from the group consisting of genistein, daidzein, cucurbitacin, prangenidin and a derivative thereof, and

wherein the insoluble biologically active substance includes H in its molecule, wherein the —H in its molecule forms a hydrogen bond with the functional group capable of forming a hydrogen bond in the second block (B) of the amphiphilic polymer.

2. The micelle of claim 1 , wherein the first block (A) is one or more selected from the group consisting of a polyethylene glycol, a polyethylene glycol-propylene glycol copolymer, a polyvinylpyrrolidone and a polyethyleneimine.

3. The micelle of claim 1 , wherein the acrylic monomer is a compound represented by the following Formula 1 or 2:

where, in Formulas 1 and 2, Q is hydrogen or an alkyl group,

in Formula 1, B is a linear or branched alkyl group with one or more carbon atoms, an alicyclic hydrocarbon group, an aromatic substituent or a carboxyl group, and

in Formula 2, R 1 and R 2 each independently represent hydrogen, a linear or branched alkyl group with one or more carbon atoms, an alicyclic hydrocarbon group, or an aromatic substituent.

4. The micelle of claim 3 , wherein, in Formula 1, Q is hydrogen or an alkyl group with 1 to 4 carbon atoms, and B is an alkyl group with one or more carbon atoms or an alicyclic hydrocarbon group with 6 to 12 carbon atoms.

5. The micelle of claim 1 , wherein the vinyl-based monomer is a compound represented by the following Formula 3 or 4:

where, in Formula 3, X is a nitrogen atom or an oxygen atom, Y is a carbonyl group or a single bond, R 3 and R 5 each independently represent hydrogen or an alkyl group, R 3 and R 5 are connected to each other to form an alkylene group, and R 4 is an alkenyl group (but, when X is an oxygen atom, R 3 is not present);

where, in Formula 4, R 6 , R 7 and R 8 each independently represent hydrogen or an alkyl group, and R 9 is a cyano group or an aromatic substituent.

6. The micelle of claim 1 , wherein the functional group is a hydroxyl group, an amine group, a nitro group, an amino group, an imide group, an alkoxysilane group or a cyano group.

7. The micelle of claim 1 , wherein a weight ratio (B1:B2) of the polymerization unit (B1) of an acrylic monomer or vinyl-based monomer of which a homopolymer has a solubility parameter of less than 10.0 (cal/cm 3 ) 1/2 to the polymerization unit (B2) of a polymerizable monomer having a functional group which is capable of forming a hydrogen bond in the second block (B) is in a range of 1:9 to 9:1.

8. The micelle of claim 1 , wherein a block ratio (A:B) of the first block to the second block is in a range of 1:9 to 9:1.

9. The micelle of claim 1 , wherein a block ratio (A:B) of the first block to the second block is in a range of 3:7 to 7:3.

10. The micelle of claim 1 , wherein an average particle size is in a range of 1 to 10,000 nm.

11. A composition for preparing a particle, comprising the micelle of claim 1 .

12. A pharmaceutical or cosmetic composition, comprising the micelle of claim 1 .

13. The pharmaceutical or cosmetic composition of claim 12 , which is in the form of water-in-oil or oil-in-water emulsion.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 12, 2017
From: YOON, JEONG AE; KIM, SU JEONG; LEE, SUN HWA; SHIM, WOO SUN; YOON, SUNG SOO; JU, CHANG HWAN; KIM, JUNG A.; KANG, NAE GYU
To: LG CHEM, LTD.; LG HOUSEHOLD & HEALTH CARE LTD.
Reel/Frame 042354/0657 →
Priority Claims (1)
KR 10-2015-0165875 · Nov 25, 2015 · national
Continuity (1)
Related Publication 20170354576A1 · Dec 14, 2017